img

Global Metachromatic Leukodystrophy Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Metachromatic Leukodystrophy Treatment Market Insights, Forecast to 2034

Metachromatic leukodystrophy disease (MLD) is a deadly genetic condition caused by mutations in the ARSA gene that results in brain impairment and developmental retardation. In its most severe and prevalent forms, young children rapidly lose their capacity to walk, communicate, and interact with their surroundings, and the majority die before reaching puberty.Metachromatic leukodystrophy is characterized by sulfatide deposition in cells. This accumulating has a particular impact on nervous system cells that create myelin, a material that insulates and protects neurons. White matter is a tissue made composed of nerve cells coated with myelin. This damages the protective myelin sheathing the neurons, leading to gradual deterioration of the brain and nervous system functioning.This disease has three forms that are Late Infantile Form, Juvenile Form, and Adult Form. Pipeline products, which can only treat symptoms of the disease, are among the medical treatment. These products have the potential to prevent nerve damage, reduce the development of the illness, avoid complications, and provide pain relief.
Market Analysis and InsightsGlobal Metachromatic Leukodystrophy Treatment Market
Global Metachromatic Leukodystrophy Treatment market is expected to reach to US$ 209 million in 2024, with a positive growth of %, compared with US$ 203 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Metachromatic Leukodystrophy Treatment industry is evaluated to reach US$ 259.9 million in 2029. The CAGR will be 3.7% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Metachromatic Leukodystrophy Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Metachromatic Leukodystrophy Treatment market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


ArmaGen, Inc.
GlaxoSmithKline Plc
Recursion Pharmaceuticals, Inc.
RegenxBio, Inc.
Takeda Pharmaceutical Company Limited
Orchard Therapeutics Plc
Magenta Therapeutics
Shire Plc
Oxyrane
NanoMedSyn
Juventas Therapeutics
GenSight Biologics
Inozyme Pharma
ONL Therapeutics
AngioChem
Cabaletta Bio
Segment by Type
Tablet
Capsule
Others

Segment by Application


Hospital
Clinic
Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Metachromatic Leukodystrophy Treatment introduction, etc. Metachromatic Leukodystrophy Treatment Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Metachromatic Leukodystrophy Treatment
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Tablet
1.2.3 Capsule
1.2.4 Others
1.3 Market by Application
1.3.1 Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laboratory
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metachromatic Leukodystrophy Treatment Market Perspective (2018-2029)
2.2 Global Metachromatic Leukodystrophy Treatment Growth Trends by Region
2.2.1 Metachromatic Leukodystrophy Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Metachromatic Leukodystrophy Treatment Historic Market Size by Region (2018-2024)
2.2.3 Metachromatic Leukodystrophy Treatment Forecasted Market Size by Region (2024-2029)
2.3 Metachromatic Leukodystrophy Treatment Market Dynamics
2.3.1 Metachromatic Leukodystrophy Treatment Industry Trends
2.3.2 Metachromatic Leukodystrophy Treatment Market Drivers
2.3.3 Metachromatic Leukodystrophy Treatment Market Challenges
2.3.4 Metachromatic Leukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Metachromatic Leukodystrophy Treatment by Players
3.1.1 Global Metachromatic Leukodystrophy Treatment Revenue by Players (2018-2024)
3.1.2 Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Metachromatic Leukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Metachromatic Leukodystrophy Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Metachromatic Leukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Metachromatic Leukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metachromatic Leukodystrophy Treatment Revenue in 2022
3.5 Global Key Players of Metachromatic Leukodystrophy Treatment Head office and Area Served
3.6 Global Key Players of Metachromatic Leukodystrophy Treatment, Product and Application
3.7 Global Key Players of Metachromatic Leukodystrophy Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Metachromatic Leukodystrophy Treatment Breakdown Data by Type
4.1 Global Metachromatic Leukodystrophy Treatment Historic Market Size by Type (2018-2024)
4.2 Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Type (2024-2029)
5 Metachromatic Leukodystrophy Treatment Breakdown Data by Application
5.1 Global Metachromatic Leukodystrophy Treatment Historic Market Size by Application (2018-2024)
5.2 Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Metachromatic Leukodystrophy Treatment Market Size (2018-2029)
6.2 North America Metachromatic Leukodystrophy Treatment Market Size by Type
6.2.1 North America Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024)
6.2.2 North America Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029)
6.2.3 North America Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
6.3 North America Metachromatic Leukodystrophy Treatment Market Size by Application
6.3.1 North America Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024)
6.3.2 North America Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029)
6.3.3 North America Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
6.4 North America Metachromatic Leukodystrophy Treatment Market Size by Country
6.4.1 North America Metachromatic Leukodystrophy Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024)
6.4.3 North America Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Metachromatic Leukodystrophy Treatment Market Size (2018-2029)
7.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Type
7.2.1 Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024)
7.2.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029)
7.2.3 Europe Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
7.3 Europe Metachromatic Leukodystrophy Treatment Market Size by Application
7.3.1 Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024)
7.3.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029)
7.3.3 Europe Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
7.4 Europe Metachromatic Leukodystrophy Treatment Market Size by Country
7.4.1 Europe Metachromatic Leukodystrophy Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024)
7.4.3 Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Metachromatic Leukodystrophy Treatment Market Size (2018-2029)
8.2 China Metachromatic Leukodystrophy Treatment Market Size by Type
8.2.1 China Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024)
8.2.2 China Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029)
8.2.3 China Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
8.3 China Metachromatic Leukodystrophy Treatment Market Size by Application
8.3.1 China Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024)
8.3.2 China Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029)
8.3.3 China Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Metachromatic Leukodystrophy Treatment Market Size (2018-2029)
9.2 Asia Metachromatic Leukodystrophy Treatment Market Size by Type
9.2.1 Asia Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024)
9.2.2 Asia Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029)
9.2.3 Asia Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
9.3 Asia Metachromatic Leukodystrophy Treatment Market Size by Application
9.3.1 Asia Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024)
9.3.2 Asia Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029)
9.3.3 Asia Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
9.4 Asia Metachromatic Leukodystrophy Treatment Market Size by Region
9.4.1 Asia Metachromatic Leukodystrophy Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2024)
9.4.3 Asia Metachromatic Leukodystrophy Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 ArmaGen, Inc.
11.1.1 ArmaGen, Inc. Company Details
11.1.2 ArmaGen, Inc. Business Overview
11.1.3 ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.1.4 ArmaGen, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.1.5 ArmaGen, Inc. Recent Developments
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Details
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.2.5 GlaxoSmithKline Plc Recent Developments
11.3 Recursion Pharmaceuticals, Inc.
11.3.1 Recursion Pharmaceuticals, Inc. Company Details
11.3.2 Recursion Pharmaceuticals, Inc. Business Overview
11.3.3 Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.3.4 Recursion Pharmaceuticals, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.3.5 Recursion Pharmaceuticals, Inc. Recent Developments
11.4 RegenxBio, Inc.
11.4.1 RegenxBio, Inc. Company Details
11.4.2 RegenxBio, Inc. Business Overview
11.4.3 RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Introduction
11.4.4 RegenxBio, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.4.5 RegenxBio, Inc. Recent Developments
11.5 Takeda Pharmaceutical Company Limited
11.5.1 Takeda Pharmaceutical Company Limited Company Details
11.5.2 Takeda Pharmaceutical Company Limited Business Overview
11.5.3 Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Introduction
11.5.4 Takeda Pharmaceutical Company Limited Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.5.5 Takeda Pharmaceutical Company Limited Recent Developments
11.6 Orchard Therapeutics Plc
11.6.1 Orchard Therapeutics Plc Company Details
11.6.2 Orchard Therapeutics Plc Business Overview
11.6.3 Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Introduction
11.6.4 Orchard Therapeutics Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.6.5 Orchard Therapeutics Plc Recent Developments
11.7 Magenta Therapeutics
11.7.1 Magenta Therapeutics Company Details
11.7.2 Magenta Therapeutics Business Overview
11.7.3 Magenta Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.7.4 Magenta Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.7.5 Magenta Therapeutics Recent Developments
11.8 Shire Plc
11.8.1 Shire Plc Company Details
11.8.2 Shire Plc Business Overview
11.8.3 Shire Plc Metachromatic Leukodystrophy Treatment Introduction
11.8.4 Shire Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.8.5 Shire Plc Recent Developments
11.9 Oxyrane
11.9.1 Oxyrane Company Details
11.9.2 Oxyrane Business Overview
11.9.3 Oxyrane Metachromatic Leukodystrophy Treatment Introduction
11.9.4 Oxyrane Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.9.5 Oxyrane Recent Developments
11.10 NanoMedSyn
11.10.1 NanoMedSyn Company Details
11.10.2 NanoMedSyn Business Overview
11.10.3 NanoMedSyn Metachromatic Leukodystrophy Treatment Introduction
11.10.4 NanoMedSyn Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.10.5 NanoMedSyn Recent Developments
11.11 Juventas Therapeutics
11.11.1 Juventas Therapeutics Company Details
11.11.2 Juventas Therapeutics Business Overview
11.11.3 Juventas Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.11.4 Juventas Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.11.5 Juventas Therapeutics Recent Developments
11.12 GenSight Biologics
11.12.1 GenSight Biologics Company Details
11.12.2 GenSight Biologics Business Overview
11.12.3 GenSight Biologics Metachromatic Leukodystrophy Treatment Introduction
11.12.4 GenSight Biologics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.12.5 GenSight Biologics Recent Developments
11.13 Inozyme Pharma
11.13.1 Inozyme Pharma Company Details
11.13.2 Inozyme Pharma Business Overview
11.13.3 Inozyme Pharma Metachromatic Leukodystrophy Treatment Introduction
11.13.4 Inozyme Pharma Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.13.5 Inozyme Pharma Recent Developments
11.14 ONL Therapeutics
11.14.1 ONL Therapeutics Company Details
11.14.2 ONL Therapeutics Business Overview
11.14.3 ONL Therapeutics Metachromatic Leukodystrophy Treatment Introduction
11.14.4 ONL Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.14.5 ONL Therapeutics Recent Developments
11.15 AngioChem
11.15.1 AngioChem Company Details
11.15.2 AngioChem Business Overview
11.15.3 AngioChem Metachromatic Leukodystrophy Treatment Introduction
11.15.4 AngioChem Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.15.5 AngioChem Recent Developments
11.16 Cabaletta Bio
11.16.1 Cabaletta Bio Company Details
11.16.2 Cabaletta Bio Business Overview
11.16.3 Cabaletta Bio Metachromatic Leukodystrophy Treatment Introduction
11.16.4 Cabaletta Bio Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024)
11.16.5 Cabaletta Bio Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Tablet
Table 3. Key Players of Capsule
Table 4. Key Players of Others
Table 5. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global Metachromatic Leukodystrophy Treatment Market Share by Region (2018-2024)
Table 9. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Metachromatic Leukodystrophy Treatment Market Share by Region (2024-2029)
Table 11. Metachromatic Leukodystrophy Treatment Market Trends
Table 12. Metachromatic Leukodystrophy Treatment Market Drivers
Table 13. Metachromatic Leukodystrophy Treatment Market Challenges
Table 14. Metachromatic Leukodystrophy Treatment Market Restraints
Table 15. Global Metachromatic Leukodystrophy Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global Metachromatic Leukodystrophy Treatment Revenue Share by Players (2018-2024)
Table 17. Global Top Metachromatic Leukodystrophy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy Treatment as of 2022)
Table 18. Global Metachromatic Leukodystrophy Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by Metachromatic Leukodystrophy Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of Metachromatic Leukodystrophy Treatment, Headquarters and Area Served
Table 21. Global Key Players of Metachromatic Leukodystrophy Treatment, Product and Application
Table 22. Global Key Players of Metachromatic Leukodystrophy Treatment, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Type (2018-2024)
Table 26. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Metachromatic Leukodystrophy Treatment Revenue Market Share by Type (2024-2029)
Table 28. Global Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global Metachromatic Leukodystrophy Treatment Revenue Share by Application (2018-2024)
Table 30. Global Metachromatic Leukodystrophy Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Metachromatic Leukodystrophy Treatment Revenue Share by Application (2024-2029)
Table 32. North America Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America Metachromatic Leukodystrophy Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe Metachromatic Leukodystrophy Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 46. China Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 47. China Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 48. China Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 49. China Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia Metachromatic Leukodystrophy Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia Metachromatic Leukodystrophy Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia Metachromatic Leukodystrophy Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 64. ArmaGen, Inc. Company Details
Table 65. ArmaGen, Inc. Business Overview
Table 66. ArmaGen, Inc. Metachromatic Leukodystrophy Treatment Product
Table 67. ArmaGen, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 68. ArmaGen, Inc. Recent Developments
Table 69. GlaxoSmithKline Plc Company Details
Table 70. GlaxoSmithKline Plc Business Overview
Table 71. GlaxoSmithKline Plc Metachromatic Leukodystrophy Treatment Product
Table 72. GlaxoSmithKline Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 73. GlaxoSmithKline Plc Recent Developments
Table 74. Recursion Pharmaceuticals, Inc. Company Details
Table 75. Recursion Pharmaceuticals, Inc. Business Overview
Table 76. Recursion Pharmaceuticals, Inc. Metachromatic Leukodystrophy Treatment Product
Table 77. Recursion Pharmaceuticals, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 78. Recursion Pharmaceuticals, Inc. Recent Developments
Table 79. RegenxBio, Inc. Company Details
Table 80. RegenxBio, Inc. Business Overview
Table 81. RegenxBio, Inc. Metachromatic Leukodystrophy Treatment Product
Table 82. RegenxBio, Inc. Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 83. RegenxBio, Inc. Recent Developments
Table 84. Takeda Pharmaceutical Company Limited Company Details
Table 85. Takeda Pharmaceutical Company Limited Business Overview
Table 86. Takeda Pharmaceutical Company Limited Metachromatic Leukodystrophy Treatment Product
Table 87. Takeda Pharmaceutical Company Limited Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 88. Takeda Pharmaceutical Company Limited Recent Developments
Table 89. Orchard Therapeutics Plc Company Details
Table 90. Orchard Therapeutics Plc Business Overview
Table 91. Orchard Therapeutics Plc Metachromatic Leukodystrophy Treatment Product
Table 92. Orchard Therapeutics Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 93. Orchard Therapeutics Plc Recent Developments
Table 94. Magenta Therapeutics Company Details
Table 95. Magenta Therapeutics Business Overview
Table 96. Magenta Therapeutics Metachromatic Leukodystrophy Treatment Product
Table 97. Magenta Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 98. Magenta Therapeutics Recent Developments
Table 99. Shire Plc Company Details
Table 100. Shire Plc Business Overview
Table 101. Shire Plc Metachromatic Leukodystrophy Treatment Product
Table 102. Shire Plc Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 103. Shire Plc Recent Developments
Table 104. Oxyrane Company Details
Table 105. Oxyrane Business Overview
Table 106. Oxyrane Metachromatic Leukodystrophy Treatment Product
Table 107. Oxyrane Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 108. Oxyrane Recent Developments
Table 109. NanoMedSyn Company Details
Table 110. NanoMedSyn Business Overview
Table 111. NanoMedSyn Metachromatic Leukodystrophy Treatment Product
Table 112. NanoMedSyn Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 113. NanoMedSyn Recent Developments
Table 114. Juventas Therapeutics Company Details
Table 115. Juventas Therapeutics Business Overview
Table 116. Juventas Therapeutics Metachromatic Leukodystrophy Treatment Product
Table 117. Juventas Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 118. Juventas Therapeutics Recent Developments
Table 119. GenSight Biologics Company Details
Table 120. GenSight Biologics Business Overview
Table 121. GenSight Biologics Metachromatic Leukodystrophy Treatment Product
Table 122. GenSight Biologics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 123. GenSight Biologics Recent Developments
Table 124. Inozyme Pharma Company Details
Table 125. Inozyme Pharma Business Overview
Table 126. Inozyme Pharma Metachromatic Leukodystrophy Treatment Product
Table 127. Inozyme Pharma Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 128. Inozyme Pharma Recent Developments
Table 129. ONL Therapeutics Company Details
Table 130. ONL Therapeutics Business Overview
Table 131. ONL Therapeutics Metachromatic Leukodystrophy Treatment Product
Table 132. ONL Therapeutics Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 133. ONL Therapeutics Recent Developments
Table 134. AngioChem Company Details
Table 135. AngioChem Business Overview
Table 136. AngioChem Metachromatic Leukodystrophy Treatment Product
Table 137. AngioChem Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 138. AngioChem Recent Developments
Table 139. Cabaletta Bio Company Details
Table 140. Cabaletta Bio Business Overview
Table 141. Cabaletta Bio Metachromatic Leukodystrophy Treatment Product
Table 142. Cabaletta Bio Revenue in Metachromatic Leukodystrophy Treatment Business (2018-2024) & (US$ Million)
Table 143. Cabaletta Bio Recent Developments
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Metachromatic Leukodystrophy Treatment Market Share by Type: 2022 VS 2029
Figure 3. Tablet Features
Figure 4. Capsule Features
Figure 5. Others Features
Figure 6. Global Metachromatic Leukodystrophy Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Metachromatic Leukodystrophy Treatment Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Laboratory Case Studies
Figure 11. Others Case Studies
Figure 12. Metachromatic Leukodystrophy Treatment Report Years Considered
Figure 13. Global Metachromatic Leukodystrophy Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Metachromatic Leukodystrophy Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Metachromatic Leukodystrophy Treatment Market Share by Region: 2022 VS 2029
Figure 16. Global Metachromatic Leukodystrophy Treatment Market Share by Players in 2022
Figure 17. Global Top Metachromatic Leukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy Treatment as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Metachromatic Leukodystrophy Treatment Revenue in 2022
Figure 19. North America Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
Figure 21. North America Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
Figure 22. North America Metachromatic Leukodystrophy Treatment Market Share by Country (2018-2029)
Figure 23. United States Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Metachromatic Leukodystrophy Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 26. Europe Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
Figure 27. Europe Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
Figure 28. Europe Metachromatic Leukodystrophy Treatment Market Share by Country (2018-2029)
Figure 29. Germany Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. France Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. U.K. Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Italy Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Russia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Nordic Countries Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. China Metachromatic Leukodystrophy Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 36. China Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
Figure 37. China Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
Figure 38. Asia Metachromatic Leukodystrophy Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 39. Asia Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
Figure 40. Asia Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
Figure 41. Asia Metachromatic Leukodystrophy Treatment Market Share by Region (2018-2029)
Figure 42. Japan Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. South Korea Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. China Taiwan Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Southeast Asia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. India Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Australia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Share by Type (2018-2029)
Figure 50. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Share by Application (2018-2029)
Figure 51. Middle East, Africa, and Latin America Metachromatic Leukodystrophy Treatment Market Share by Country (2018-2029)
Figure 52. Brazil Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 53. Mexico Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Turkey Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Israel Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. GCC Countries Metachromatic Leukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. ArmaGen, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 59. GlaxoSmithKline Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 60. Recursion Pharmaceuticals, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 61. RegenxBio, Inc. Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 62. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 63. Orchard Therapeutics Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 64. Magenta Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 65. Shire Plc Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 66. Oxyrane Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 67. NanoMedSyn Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 68. Juventas Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 69. GenSight Biologics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 70. Inozyme Pharma Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 71. ONL Therapeutics Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 72. AngioChem Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 73. Cabaletta Bio Revenue Growth Rate in Metachromatic Leukodystrophy Treatment Business (2018-2024)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries